Cargando…

Metformin – a new approach

Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant...

Descripción completa

Detalles Bibliográficos
Autor principal: Cwynar-Zając, Łucja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214935/
https://www.ncbi.nlm.nih.gov/pubmed/34514769
http://dx.doi.org/10.5114/pedm.2021.107166
_version_ 1785047944489074688
author Cwynar-Zając, Łucja
author_facet Cwynar-Zając, Łucja
author_sort Cwynar-Zając, Łucja
collection PubMed
description Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases.
format Online
Article
Text
id pubmed-10214935
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-102149352023-06-05 Metformin – a new approach Cwynar-Zając, Łucja Pediatr Endocrinol Diabetes Metab Review paper | Praca poglądowa Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases. Termedia Publishing House 2021-06-20 2021-06 /pmc/articles/PMC10214935/ /pubmed/34514769 http://dx.doi.org/10.5114/pedm.2021.107166 Text en Copyright © Polish Society of Pediatric Endocrinology and Diabetes https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), allowing third parties to download and share its works but not commercially purposes or to create derivative works.
spellingShingle Review paper | Praca poglądowa
Cwynar-Zając, Łucja
Metformin – a new approach
title Metformin – a new approach
title_full Metformin – a new approach
title_fullStr Metformin – a new approach
title_full_unstemmed Metformin – a new approach
title_short Metformin – a new approach
title_sort metformin – a new approach
topic Review paper | Praca poglądowa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214935/
https://www.ncbi.nlm.nih.gov/pubmed/34514769
http://dx.doi.org/10.5114/pedm.2021.107166
work_keys_str_mv AT cwynarzajacłucja metforminanewapproach